Vincenzo Tortora

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Background: Cabazitaxel is a second-generation taxane that is approved for use with concomitant low dose daily prednisone in metastatic castration resistant prostate cancer (mCRPC) after docetaxel failure. Since the role of daily corticosteroids in improving cabazitaxel efficacy or ameliorating its safety profile has not been adequately investigated so far,(More)
  • 1